{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:13:08Z","timestamp":1784146388189,"version":"3.55.0"},"reference-count":37,"publisher":"Walter de Gruyter GmbH","issue":"9","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2024-1312_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Primary aldosteronism (PA) is a common cause of secondary hypertension. The aldosterone-to-renin ratio (ARR) is the current recommended biomarker for PA screening, but it has limitations. This study evaluates another ratio, the aldosterone-to-angiotensin II ratio (AAIIR), as an alternative screening tool for PA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-1312_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Archived plasma samples for ARR from a group of 152 hypertensive patients undergoing PA screening were retrieved for AAIIR analyses. Both AAIIR and ARR were measured by liquid chromatography-mass spectrometry methods. Correlation analysis, sensitivity, specificity, and receiver operating characteristic (ROC) curve analysis were performed to assess the diagnostic performance of AAIIR relative to ARR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-1312_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AAIIR showed a strong positive correlation with ARR (r=0.79, p&lt;0.0001). The area under the ROC curve for AAIIR (0.94, 95\u202f% CI: 0.90\u20130.98) was satisfactory and not significantly different from ARR (0.94, 95\u202f% CI: 0.90\u20130.97, p=0.877). The optimal cutoff values were 577 (pmol\/L)\/(\u00b5g\/L\n                      <jats:sup>\u2212h<\/jats:sup>\n                      ) and 60 for ARR and AAIIR, respectively. The sensitivity of AAIIR was slightly higher than ARR (91 vs. 88\u202f%), while the specificity was comparable (85 vs. 86\u202f%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2024-1312_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AAIIR demonstrates a comparable diagnostic performance to ARR for PA screening, with potential advantages in efficiency and reliability. Further large-scale studies are needed to validate its efficacy and establish its role in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2024-1312","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:32:11Z","timestamp":1743751931000},"page":"1749-1756","source":"Crossref","is-referenced-by-count":3,"title":["Screening primary aldosteronism by plasma aldosterone-to-angiotensin II ratio"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-298X","authenticated-orcid":false,"given":"Clara Wai-Shan","family":"Lo","sequence":"first","affiliation":[{"name":"Department of Chemical Pathology , 26451 The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Yeuk-Ki","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology , 26451 The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Kam-Chi","family":"Tsui","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology , 26451 The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Ching-Wan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics , The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Ho-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology , 26451 The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics , The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Shun","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology , 26451 The Chinese University of Hong Kong, Prince of Wales Hospital , Statin , NT , Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2026051215061113861_j_cclm-2024-1312_ref_001","doi-asserted-by":"crossref","unstructured":"Cohen, JB, Bancos, I, Brown, JM, Sarathy, H, Turcu, AF, Cohen, DL. Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys. Annu Rev Med 2023;74:217\u201330. https:\/\/doi.org\/10.1146\/annurev-med-042921-100438.","DOI":"10.1146\/annurev-med-042921-100438"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_002","doi-asserted-by":"crossref","unstructured":"Funder, JW, Carey, RM, Mantero, F, Murad, MH, Reincke, M, Shibata, H, et al.. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889\u2013916. https:\/\/doi.org\/10.1210\/jc.2015-4061.","DOI":"10.1210\/jc.2015-4061"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_003","doi-asserted-by":"crossref","unstructured":"Raizman, JE, Diamandis, EP, Holmes, D, Stowasser, M, Auchus, R, Cavalier, E. A renin-ssance in primary aldosteronism testing: obstacles and opportunities for screening, diagnosis, and management. Clin Chem 2015;61:1022\u20137. https:\/\/doi.org\/10.1373\/clinchem.2015.242990.","DOI":"10.1373\/clinchem.2015.242990"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_004","doi-asserted-by":"crossref","unstructured":"Gordon, DB, Sachin, IN. Simultaneous measurement of PRA, PRC and PRR and the relation of renin reaction rate to renin substrate concentration. Clin Exp Hypertens(1978) 1980;2:65\u201387. https:\/\/doi.org\/10.3109\/10641968009038552.","DOI":"10.3109\/10641968009038552"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_005","doi-asserted-by":"crossref","unstructured":"Campbell, DJ, Nussberger, J, Stowasser, M, Danser, AH, Morganti, A, Frandsen, E, et al.. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009;55:867\u201377. https:\/\/doi.org\/10.1373\/clinchem.2008.118000.","DOI":"10.1373\/clinchem.2008.118000"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_006","doi-asserted-by":"crossref","unstructured":"Hartman, D, Sagnella, GA, Chesters, CA, Macgregor, GA. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004;50:2159\u201361. https:\/\/doi.org\/10.1373\/clinchem.2004.033654.","DOI":"10.1373\/clinchem.2004.033654"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_007","doi-asserted-by":"crossref","unstructured":"Lo, CWS, Tsui, TKC, Ma, RCW, Chan, MHM, Ho, CS. Quantitation of plasma angiotensin II in healthy Chinese subjects by a validated liquid chromatography tandem mass spectrometry method. Biomed Chromatogr 2022;36. https:\/\/doi.org\/10.1002\/bmc.5318.","DOI":"10.1002\/bmc.5318"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_008","doi-asserted-by":"crossref","unstructured":"Ali, Q, Wu, Y, Nag, S, Hussain, T. Estimation of angiotensin peptides in biological samples by LC\/MS method. Anal Methods 2014;6:215\u201322. https:\/\/doi.org\/10.1039\/c3ay41305e.","DOI":"10.1039\/C3AY41305E"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_009","doi-asserted-by":"crossref","unstructured":"Das, R, Pal, TK. Method development and validation of liquid chromatography-tandem mass spectrometry for angiotensin-II in human plasma: application to study interaction between atorvastatin and olmesartan drug combination. Indian J Clin Biochem 2015;30:334\u201344. https:\/\/doi.org\/10.1007\/s12291-014-0457-x.","DOI":"10.1007\/s12291-014-0457-x"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_010","doi-asserted-by":"crossref","unstructured":"Olkowicz, M, Radulska, A, Suraj, J, Kij, A, Walczak, M, Chlopicki, S, et al.. Development of a sensitive, accurate and robust liquid chromatography\/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice. J Chromatogr A 2015;1393:37\u201346. https:\/\/doi.org\/10.1016\/j.chroma.2015.03.012.","DOI":"10.1016\/j.chroma.2015.03.012"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_011","doi-asserted-by":"crossref","unstructured":"Schulz, A, Jankowski, J, Zidek, W, Jankowski, V. Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS\/MS. Clin Proteom 2014;11:37. https:\/\/doi.org\/10.1186\/1559-0275-11-37.","DOI":"10.1186\/1559-0275-11-37"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_012","doi-asserted-by":"crossref","unstructured":"Bernstone, L, Adaway, JE, Keevil, BG. An LC-MS\/MS assay for analysis of equilibrium angiotensin II in human serum. Ann Clin Biochem 2021;58:422\u201333. https:\/\/doi.org\/10.1177\/00045632211008923.","DOI":"10.1177\/00045632211008923"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_013","doi-asserted-by":"crossref","unstructured":"Guo, Z, Poglitsch, M, McWhinney, BC, Ungerer, JPJ, Ahmed, AH, Gordon, RD, et al.. Measurement of equilibrium angiotensin II in\u00a0the\u00a0diagnosis of primary aldosteronism. Clin Chem 2020;66:483\u201392. https:\/\/doi.org\/10.1093\/clinchem\/hvaa001.","DOI":"10.1093\/clinchem\/hvaa001"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_014","doi-asserted-by":"crossref","unstructured":"Zeng, W, Chu, TTW, Ho, CS, Lo, CWS, Chan, ASL, Kong, APS, et al.. Lack of effects of renin-angiotensin-aldosterone system activity and beta-adrenoceptor pathway polymorphisms on the response to bisoprolol in hypertension. Front Cardiovasc Med 2022;9:842875. https:\/\/doi.org\/10.3389\/fcvm.2022.842875.","DOI":"10.3389\/fcvm.2022.842875"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_015","doi-asserted-by":"crossref","unstructured":"Bystrom, CE, Salameh, W, Reitz, R, Clarke, NJ. Plasma renin activity by LC-MS\/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem 2010;56:1561\u20139. https:\/\/doi.org\/10.1373\/clinchem.2010.146449.","DOI":"10.1373\/clinchem.2010.146449"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_016","doi-asserted-by":"crossref","unstructured":"Carter, S, Owen, LJ, Kerstens, MN, Dullaart, RP, Keevil, BG. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012;49:570\u20139. https:\/\/doi.org\/10.1258\/acb.2012.011186.","DOI":"10.1258\/acb.2012.011186"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_017","doi-asserted-by":"crossref","unstructured":"van Rooyen, JM, Poglitsch, M, Huisman, HW, Mels, C, Kruger, R, Malan, L, et al.. Quantification of systemic renin-angiotensin system peptides of hypertensive black and white African men established from the RAS-Fingerprint(R). J Renin Angiotensin Aldosterone Syst. 2016;17. https:\/\/doi.org\/10.1177\/1470320316669880.","DOI":"10.1177\/1470320316669880"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_018","doi-asserted-by":"crossref","unstructured":"Mulrow, PJ. Angiotensin II and aldosterone regulation. Regul Pept 1999;80:27\u201332. https:\/\/doi.org\/10.1016\/s0167-0115(99)00004-x.","DOI":"10.1016\/S0167-0115(99)00004-X"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_019","doi-asserted-by":"crossref","unstructured":"Vaidya, A, Mulatero, P, Baudrand, R, Adler, GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018;39:1057\u201388. https:\/\/doi.org\/10.1210\/er.2018-00139.","DOI":"10.1210\/er.2018-00139"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_020","unstructured":"Papadopoulou-Marketou, N, Vaidya, A, Dluhy, R, Chrousos, GP. In: Feingold, KR, Anawalt, B, Blackman, MR, Boyce, A, Chrousos, G, Corpas, E, et al.., editors. Hyperaldosteronism. South Dartmouth (MA): Endotext; 2000."},{"key":"2026051215061113861_j_cclm-2024-1312_ref_021","doi-asserted-by":"crossref","unstructured":"Monticone, S, Losano, I, Tetti, M, Buffolo, F, Veglio, F, Mulatero, P. Diagnostic approach to low-renin hypertension. Clin Endocrinol (Oxf) 2018;89:385\u201396. https:\/\/doi.org\/10.1111\/cen.13741.","DOI":"10.1111\/cen.13741"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_022","doi-asserted-by":"crossref","unstructured":"Sahay, M, Sahay, RK. Low renin hypertension. Indian J Endocrinol Metab 2012;16:728\u201339. https:\/\/doi.org\/10.4103\/2230-8210.100665.","DOI":"10.4103\/2230-8210.100665"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_023","doi-asserted-by":"crossref","unstructured":"Calhoun, DA, Sharma, K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin 2010;28:517\u201327. https:\/\/doi.org\/10.1016\/j.ccl.2010.04.001.","DOI":"10.1016\/j.ccl.2010.04.001"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_024","doi-asserted-by":"crossref","unstructured":"Lim, PO, Dow, E, Brennan, G, Jung, RT, MacDonald, TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000;14:311\u20135. https:\/\/doi.org\/10.1038\/sj.jhh.1001013.","DOI":"10.1038\/sj.jhh.1001013"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_025","doi-asserted-by":"crossref","unstructured":"Loh, KC, Koay, ES, Khaw, MC, Emmanuel, SC, Young, WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocr Metab 2000;85:2854\u20139. https:\/\/doi.org\/10.1210\/jcem.85.8.6752.","DOI":"10.1210\/jc.85.8.2854"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_026","doi-asserted-by":"crossref","unstructured":"Mulatero, P, Stowasser, M, Loh, KC, Fardella, CE, Gordon, RD, Mosso, L, et al.. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Hypertens 2004;22:S182\u2013S. https:\/\/doi.org\/10.1097\/00004872-200406002-00629.","DOI":"10.1097\/00004872-200406002-00629"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_027","doi-asserted-by":"crossref","unstructured":"Sang, XJ, Jiang, YR, Wang, WQ, Yan, L, Zhao, JS, Peng, YD, et al.. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 2013;31:1465\u201372. https:\/\/doi.org\/10.1097\/hjh.0b013e328360ddf6.","DOI":"10.1097\/HJH.0b013e328360ddf6"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_028","unstructured":"Sy, WM, Fu, SN, Luk, W, Wong, CKH, Fung, LM. Primary hyperaldosteronism among Chinese hypertensive patients: how are we doing in a local district in Hong Kong. Hong Kong Med J 2012;18:193\u2013200."},{"key":"2026051215061113861_j_cclm-2024-1312_ref_029","doi-asserted-by":"crossref","unstructured":"Akintunde, AA, Salawu, AA, Oloyede, T, Adeniyi, DB. Renin activity and aldosterone assay among Nigerians with hypertension and normotension: an insight into normative values and clinical correlates. Curr Hypertens Rev 2018;14:29\u201334. https:\/\/doi.org\/10.2174\/1573402114666171213145049.","DOI":"10.2174\/1573402114666171213145049"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_030","doi-asserted-by":"crossref","unstructured":"Buffolo, F, Monticone, S, Burrello, J, Tetti, M, Veglio, F, Williams, TA, et al.. Is primary aldosteronism still largely unrecognized? Horm Metab Res 2017;49:908\u201314. https:\/\/doi.org\/10.1055\/s-0043-119755.","DOI":"10.1055\/s-0043-119755"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_031","doi-asserted-by":"crossref","unstructured":"Fagugli, RM, Taglioni, C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens 2011;2011. https:\/\/doi.org\/10.4061\/2011\/162804.","DOI":"10.4061\/2011\/162804"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_032","doi-asserted-by":"crossref","unstructured":"Fogari, R, Preti, P, Zoppi, A, Rinaldi, A, Fogari, E, Mugellini, A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone\/renin ratio above 25 as a screening test. Hypertens Res 2007;30:111\u20137. https:\/\/doi.org\/10.1291\/hypres.30.111.","DOI":"10.1291\/hypres.30.111"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_033","doi-asserted-by":"crossref","unstructured":"Plouin, PF, Amar, L, Chatellier, G. Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transpl 2004;19:774\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfh112.","DOI":"10.1093\/ndt\/gfh112"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_034","doi-asserted-by":"crossref","unstructured":"Rossi, E, Perazzoli, F, Negro, A, Magnani, A. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000-2015). J Hypertens 2017;35:1691\u20137. https:\/\/doi.org\/10.1097\/hjh.0000000000001384.","DOI":"10.1097\/HJH.0000000000001384"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_035","doi-asserted-by":"crossref","unstructured":"Feinstein, AR. Clinical epidemiology\u00a0\u2013 the architecture of clinical Research. Stat Med 1995;14:1263. https:\/\/doi.org\/10.1002\/sim.4780141110.","DOI":"10.1002\/sim.4780141110"},{"key":"2026051215061113861_j_cclm-2024-1312_ref_038","unstructured":"Kramer, MS. Clinical epidemiology and biostatistics. Berlin, Heidelberg: Springer Berlin Heidelberg; 1988."},{"key":"2026051215061113861_j_cclm-2024-1312_ref_037","doi-asserted-by":"crossref","unstructured":"Hayden, SR, Brown, MD. Likelihood ratio: a powerful tool for incorporating the results of a diagnostic test into clinical decision making. Ann Emerg Med 1999;33:575\u201380. https:\/\/doi.org\/10.1016\/s0196-0644(99)70346-x.","DOI":"10.1016\/S0196-0644(99)70346-X"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1312\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1312\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:14:11Z","timestamp":1778598851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1312\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,8,26]]}},"alternative-id":["10.1515\/cclm-2024-1312"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-1312","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}